Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Biotech
Biotech — Sep 7 – Sep 11, 2026 (Wk 37): Biotech Risk Score Rises; Novartis Faces Setback, Encoded Therapeutics Sees Investment →The biotech sector's risk score increased this week, indicating a potentially more volatile environment. Novartis experienced a clinical trial failure, while RTW Biotech Opportunities made an additional investment in Encoded Therapeutics, highlighting continued activity in specific…
TRDA
Valuation N/A
Entrada Therapeutics, Inc.
Price$6.80
Model IV—
P/IV—
Market implies +34.2%/yr
vs model +15.0% · above model
TRIB
Valuation N/A
TRINITY BIOTECH PLC
Price$7.74
Model IV—
P/IV—
Limited data — see page
TRVI
Valuation N/A
Trevi Therapeutics, Inc.
Price$15.90
Model IV—
P/IV—
Limited data — see page
TSHA
Valuation N/A
Taysha Gene Therapies, Inc.
Price$5.02
Model IV—
P/IV—
Market implies +83.9%/yr
vs model +15.0% · above model
TTRX
Valuation N/A
Turn Therapeutics Inc.
Price$12.69
Model IV—
P/IV—
Limited data — see page
TVGN
Valuation N/A
Tevogen Inc.
Price$7.36
Model IV—
P/IV—
Limited data — see page
TVRD
Valuation N/A
Tvardi Therapeutics, Inc.
Price$1.87
Model IV—
P/IV—
Market implies -1.3%/yr
vs model +15.0% · below model
TVTX
Deeply overvalued
Travere Therapeutics, Inc.
Price$66.17
Model IV$22.11
P/IV2.13
Premium +199%
Return to IV: -66.6%
Market implies +18.7%/yr
vs model +38.9% · below model
TWST
Valuation N/A
Twist Bioscience Corp
Price$127.22
Model IV—
P/IV—
Market implies +49.9%/yr
vs model +29.9% · above model
TXG
Valuation N/A
10x Genomics, Inc.
Price$74.39
Model IV—
P/IV—
Market implies +41.7%/yr
vs model +7.0% · above model
TXMD
Deeply undervalued
TherapeuticsMD, Inc.
Price$2.16
Model IV$4.25
P/IV0.50
Discount 49%
Return to IV: +96.5%
Market implies -7.0%/yr
vs model +5.9% · below model
TYRA
Valuation N/A
Tyra Biosciences, Inc.
Price$22.03
Model IV—
P/IV—
Limited data — see page
UPB
Valuation N/A
Upstream Bio, Inc.
Price$5.73
Model IV—
P/IV—
Market implies +66.4%/yr
vs model +9.5% · above model
UPC
Valuation N/A
Universe Pharmaceuticals INC
Price$4.46
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +50.0% · below model
URGN
Valuation N/A
UroGen Pharma Ltd.
Price$42.31
Model IV—
P/IV—
Market implies +37.7%/yr
vs model +23.0% · above model
VACH
Valuation N/A
VACH
Price$17.11
Model IV—
P/IV—
Limited data — see page
VALN
Valuation N/A
Valneva SE
Price$6.66
Model IV—
P/IV—
Limited data — see page
VCEL
Deeply overvalued
Vericel Corp
Price$39.60
Model IV$10.16
P/IV3.28
Premium +290%
Return to IV: -74.3%
Market implies +17.2%/yr
vs model +15.9% · in line
VEEV
Fairly valued
VEEVA SYSTEMS INC
Price$262.40
Model IV$181.15
P/IV0.96
Premium +45%
Return to IV: -31.0%
Market implies +16.1%/yr
vs model +13.8% · in line
VERA
Valuation N/A
Vera Therapeutics, Inc.
Price$35.05
Model IV—
P/IV—
Limited data — see page
VERU
Valuation N/A
VERU INC.
Price$2.44
Model IV—
P/IV—
Market implies +10.6%/yr
vs model +15.0% · below model
VIR
Valuation N/A
Vir Biotechnology, Inc.
Price$10.62
Model IV—
P/IV—
Market implies +82.0%/yr
vs model +2.0% · above model
VIVS
Valuation N/A
VivoSim Labs, INC.
Price$0.28
Model IV—
P/IV—
Market implies -7.8%/yr
vs model +15.0% · below model
VKTX
Valuation N/A
Viking Therapeutics, Inc.
Price$31.98
Model IV—
P/IV—
Limited data — see page
VNDA
Deeply overvalued
Vanda Pharmaceuticals Inc.
Price$5.09
Model IV$2.13
P/IV3.03
Premium +139%
Return to IV: -58.2%
Market implies +9.5%/yr
vs model +2.0% · above model
VOR
Valuation N/A
Vor Biopharma Inc.
Price$22.30
Model IV—
P/IV—
Limited data — see page
VRAX
Valuation N/A
Virax Biolabs Group Ltd
Price$2.67
Model IV—
P/IV—
Market implies +101.4%/yr
vs model +2.0% · above model
VRDN
Deeply overvalued
Viridian Therapeutics, Inc.DE
Price$21.24
Model IV$4.37
P/IV4.03
Premium +386%
Return to IV: -79.4%
Market implies +20.6%/yr
vs model +50.0% · below model
VSTM
Deeply overvalued
Verastem, Inc.
Price$7.34
Model IV$2.42
P/IV1.79
Premium +204%
Return to IV: -67.1%
Market implies +15.7%/yr
vs model +50.0% · below model
VTGN
Valuation N/A
Vistagen Therapeutics, Inc.
Price$0.24
Model IV—
P/IV—
Market implies +40.3%/yr
vs model +2.0% · above model
VTVT
Valuation N/A
vTv Therapeutics Inc.
Price$31.97
Model IV—
P/IV—
Limited data — see page
VYGR
Valuation N/A
Voyager Therapeutics, Inc.
Price$3.19
Model IV—
P/IV—
Market implies +67.5%/yr
vs model +2.0% · above model
VYNE
Valuation N/A
VYNE Therapeutics Inc.
Price$27.85
Model IV—
P/IV—
Market implies +139.1%/yr
vs model +2.0% · above model
WHWK
Valuation N/A
Whitehawk Therapeutics, Inc.
Price$4.11
Model IV—
P/IV—
Market implies +74.9%/yr
vs model +2.0% · above model
WST
Deeply overvalued
WEST PHARMACEUTICAL SERVICES INC
Price$346.23
Model IV$123.32
P/IV2.62
Premium +181%
Return to IV: -64.4%
Market implies +18.4%/yr
vs model +5.7% · above model
WVE
Valuation N/A
Wave Life Sciences Ltd.
Price$4.59
Model IV—
P/IV—
Market implies +90.1%/yr
vs model +2.0% · above model
XBIO
Deeply overvalued
Xenetic Biosciences, Inc.
Price$3.90
Model IV$2.04
P/IV1.54
Premium +91%
Return to IV: -47.7%
Market implies +7.6%/yr
vs model +26.5% · below model
XBIT
Valuation N/A
XBiotech Inc.
Price$2.19
Model IV—
P/IV—
Market implies +31.0%/yr
vs model +15.0% · above model
XCUR
Valuation N/A
EXICURE, INC.
Price$1.31
Model IV—
P/IV—
Market implies +28.7%/yr
vs model +15.0% · above model
XENE
Valuation N/A
Xenon Pharmaceuticals Inc.
Price$58.65
Model IV—
P/IV—
Market implies +111.3%/yr
vs model +2.0% · above model
XFOR
Valuation N/A
X4 Pharmaceuticals, Inc
Price$3.62
Model IV—
P/IV—
Market implies +38.9%/yr
vs model +15.0% · above model
XLO
Fairly valued
Xilio Therapeutics, Inc.
Price$8.93
Model IV$8.45
P/IV1.00
Premium +6%
Return to IV: -5.3%
Market implies -7.3%/yr
vs model +15.0% · below model
XNCR
Valuation N/A
Xencor Inc
Price$24.41
Model IV—
P/IV—
Market implies +65.5%/yr
vs model +2.0% · above model
XOMA
Valuation N/A
XOMA Royalty Corp
Price$40.17
Model IV—
P/IV—
Market implies +69.6%/yr
vs model +2.0% · above model
XOMAO
Valuation N/A
XOMA Royalty Corp
Price$25.00
Model IV—
P/IV—
Market implies +72.6%/yr
vs model +2.0% · above model
XOMAP
Valuation N/A
XOMA Royalty Corp
Price$24.98
Model IV—
P/IV—
Market implies +37.2%/yr
vs model +2.0% · above model
XTLB
Valuation N/A
XTL BIOPHARMACEUTICALS LTD
Price$2.56
Model IV—
P/IV—
Market implies +147.5%/yr
vs model +15.0% · above model
XTNT
Deeply undervalued
Xtant Medical Holdings, Inc.
Price$0.35
Model IV$1.96
P/IV0.24
Discount 82%
Return to IV: +467.8%
Market implies -9.4%/yr
vs model +20.3% · below model
XXII
Valuation N/A
22nd Century Group, Inc.
Price$1.99
Model IV—
P/IV—
Market implies -30.0%/yr
vs model +2.0% · below model
YDES
Valuation N/A
YD Bio Ltd
Price$4.00
Model IV—
P/IV—
Market implies +43.8%/yr
vs model +30.6% · above model
ZBIO
Valuation N/A
Zenas BioPharma, Inc.
Price$31.12
Model IV—
P/IV—
Market implies +92.3%/yr
vs model +2.0% · above model
ZLAB
Valuation N/A
Zai Lab Ltd
Price$24.14
Model IV—
P/IV—
Market implies +37.3%/yr
vs model +33.5% · above model
ZNTL
Valuation N/A
Zentalis Pharmaceuticals, Inc.
Price$3.51
Model IV—
P/IV—
Market implies +22.0%/yr
vs model +15.0% · above model
ZURA
Valuation N/A
Zura Bio Ltd
Price$5.21
Model IV—
P/IV—
Limited data — see page
ZVRA
Fairly valued
ZEVRA THERAPEUTICS, INC.
Price$12.05
Model IV$12.28
P/IV0.94
Discount 2%
Return to IV: +1.9%
Market implies -5.2%/yr
vs model +38.8% · below model
ZYBT
Deeply overvalued
Zhengye Biotechnology Holding Ltd
Price$1.55
Model IV$0.39
P/IV2.18
Premium +297%
Return to IV: -74.8%
Market implies +24.0%/yr
vs model +10.0% · above model
ZYME
Deeply overvalued
Zymeworks Inc.
Price$26.24
Model IV$8.98
P/IV2.80
Premium +192%
Return to IV: -65.8%
Market implies +9.7%/yr
vs model +41.2% · below model